Pharmaceuticals

Angiotensin Receptor Blockers (ARBs) Industry Forecast to Hit $10.52 Billion by 2029 With a Strong 4.6% CAGR

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Angiotensin Receptor Blockers (ARBs) Market?

The market size for angiotensin receptor blockers (ARBs) has demonstrated consistent growth in recent years. It is anticipated to expand from $8.51 billion in 2024 to $8.78 billion in 2025, at a compound annual growth rate (CAGR) of 3.1%. The growth observed in the historic period is attributable to the hypertension epidemic, their clinical efficacy, the burden of cardiovascular disease, renal protection, supportive clinical guidelines, ARBs being a first-line treatment, and their cost-effectiveness.

The market size for angiotensin receptor blockers (arbs) is anticipated to demonstrate steady expansion over the next few years, projected to reach “$10.52 billion by 2029, at a compound annual growth rate (CAGR) of 4.6%.” This expected growth within the forecast period can be ascribed to several factors, including precision medicine approaches, an increased focus on combination therapies, the global expansion of the market, biomarker-based treatment strategies, government initiatives, and a greater awareness of hypertension. Key trends identified for the forecast period involve the widespread adoption of telemedicine, significant investments in research and development, growing generic competition alongside patent expirations, the deployment of digital health solutions aimed at improving medication adherence, and the rise of biosimilar competition.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which Drivers Are Impacting The Angiotensin Receptor Blockers (ARBs) Market?

The rising occurrence of cardiovascular diseases is anticipated to stimulate the expansion of the angiotensin receptor blockers market moving forward. Cardiovascular disease (CVD) encompasses any ailment affecting the heart or blood vessels, frequently linked to the accumulation of fatty deposits within arteries (atherosclerosis) and a heightened risk of blood clots. Angiotensin receptor blockers function by lowering blood pressure and enhancing the heart’s pumping capability through assisting in vein and artery relaxation, which can diminish the likelihood of cardiovascular disease. For example, in August 2022, according to the American College of Cardiology, a US-based professional medical organization, the projected rates of cardiovascular risk factors and disease are set to significantly increase in the United States by the year 2060. Consequently, the growing incidence of cardiovascular diseases is driving the growth of the angiotensin receptor blockers market.

What Are The Major Segment Types Covered In The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

What Are The Major Trends Driving The Growth Of The Angiotensin Receptor Blockers (ARBs) Market?

Leading companies in the angiotensin receptor blocker market are developing advanced products, such as angiotensin receptor neprilysin inhibitors, to enhance treatment options and improve outcomes for patients with cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) are a class of medications used to treat heart failure. For instance, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, introduced sacubitril + valsartan tablets, which are specialized for the treatment of heart failure, specifically targeting heart failure with reduced ejection fraction (HFrEF). This combination belongs to the class of medications known as ARNI (angiotensin receptor neprilysin inhibitors). Sacubitril works by enhancing the natriuretic peptide (NP) system, which helps alleviate fluid overload and promotes blood vessel dilation, while valsartan blocks the renin-angiotensin system (RAS) to lower blood pressure and reduce the heart’s workload. Together, these components effectively improve heart failure symptoms, lower the risk of cardiovascular mortality, and decrease the chances of hospitalization due to heart failure. They are marketed under the brand name Sacu V.

Who Are The Key Multinational Companies Dominating The Angiotensin Receptor Blockers (ARBs) Market?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Angiotensin Receptor Blockers (ARBs) Market?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Angiotensin Receptor Blockers (ARBs) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

Browse Through More Reports Similar to the Global Angiotensin Receptor Blockers (ARBs) Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Convalescent Plasma Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Patient Blood Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795